Literature DB >> 27746876

Post-Transplant Lymphoproliferative Disorder Presenting as CD20-Negative Plasmablastic Lymphoma in the Lung.

Tasneem Kaleem1, Jennifer A Crozier2, David M Menke3, Taimur Sher2.   

Abstract

Post-transplant lymphoproliferative disorders (PTLD) are a serious complication of transplantation with a high mortality. Most PTLD present within the first year of transplantation and are associated with Epstein-Barr virus (EBV) infection. Plasmablastic lymphoma (PBL) is a rare but aggressive disease originally described in patients with HIV, presenting most commonly in the jaw and oral mucosa. To our knowledge, this is the first case of PBL presenting as PTLD of the lung in a HIV and EBV negative patient. Given the increasing number of transplants performed, we would like to share this uncommon presentation of PTLD as PBL.

Entities:  

Keywords:  Post-transplant; lung; lymphomas; plasmablastic

Year:  2016        PMID: 27746876      PMCID: PMC5064292          DOI: 10.4081/rt.2016.6220

Source DB:  PubMed          Journal:  Rare Tumors        ISSN: 2036-3605


  12 in total

Review 1.  Epstein-Barr virus: evasive maneuvers in the development of PTLD.

Authors:  Andrew L Snow; Olivia M Martinez
Journal:  Am J Transplant       Date:  2007-01-04       Impact factor: 8.086

2.  Cutaneous presentation of plasmablastic post-transplant lymphoproliferative disorder in a 14-month-old.

Authors:  Claudia Hernandez; Aaron S Cetner; Elizabeth L Wiley
Journal:  Pediatr Dermatol       Date:  2009 Nov-Dec       Impact factor: 1.588

Review 3.  Therapy for transplant-related lymphoproliferative diseases.

Authors:  M Benkerrou; A Durandy; A Fischer
Journal:  Hematol Oncol Clin North Am       Date:  1993-04       Impact factor: 3.722

Review 4.  Identifying the patient at risk for post-transplant lymphoproliferative disorder.

Authors:  S M Cockfield
Journal:  Transpl Infect Dis       Date:  2001-06       Impact factor: 2.228

5.  CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients.

Authors:  J Teruya-Feldstein; E Chiao; D A Filippa; O Lin; R Comenzo; M Coleman; C Portlock; A Noy
Journal:  Ann Oncol       Date:  2004-11       Impact factor: 32.976

6.  Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection.

Authors:  H J Delecluse; I Anagnostopoulos; F Dallenbach; M Hummel; T Marafioti; U Schneider; D Huhn; A Schmidt-Westhausen; P A Reichart; U Gross; H Stein
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

7.  Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.

Authors:  Jorge J Castillo; Michael Furman; Brady E Beltrán; Michele Bibas; Mark Bower; Weina Chen; José L Díez-Martín; Jane J Liu; Roberto N Miranda; Silvia Montoto; Nahid M Nanaji; José-Tomás Navarro; Adam C Seegmiller; Julie M Vose
Journal:  Cancer       Date:  2012-04-17       Impact factor: 6.860

Review 8.  Plasmablastic lymphoma of the lung: report of a unique case and review of the literature.

Authors:  Y Lin; G D Rodrigues; J F Turner; M A Vasef
Journal:  Arch Pathol Lab Med       Date:  2001-02       Impact factor: 5.534

9.  Lymphomas after solid organ transplantation: a collaborative transplant study report.

Authors:  Gerhard Opelz; Bernd Döhler
Journal:  Am J Transplant       Date:  2004-02       Impact factor: 8.086

10.  Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation.

Authors:  R S Shapiro; K McClain; G Frizzera; K J Gajl-Peczalska; J H Kersey; B R Blazar; D C Arthur; D F Patton; J S Greenberg; B Burke
Journal:  Blood       Date:  1988-05       Impact factor: 22.113

View more
  1 in total

1.  CD20/CD79a/PAX5/CD3-negative post-transplant lymphoma with aberrant actin and desmin co-expression-a potential differential diagnostic pitfall between PTLD and PTSMT.

Authors:  Jan-Theile Suhren; Jerome Schlué; Hans Kreipe; Kais Hussein
Journal:  Ann Hematol       Date:  2022-02-18       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.